TY - JOUR
T1 - Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis
AU - Fuschillo, Giacomo
AU - Celentano, Valerio
AU - Rottoli, Matteo
AU - Sciaudone, Guido
AU - Gravina, Antonietta Gerarda
AU - Pellegrino, Raffaele
AU - Marfella, Raffaele
AU - Romano, Marco
AU - Selvaggi, Francesco
AU - Pellino, Gianluca
N1 - Publisher Copyright:
© 2022
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Background: Diabetes Mellitus (DM) may occur in IBD and influence the disease progression. Aim: To compare disease course and treatment outcomes in IBD patients with and without DM. Methods: This is a systematic review with meta-analysis comparing patients with IBD plus DM with patients with IBD only. Primary endpoints: need for surgery, IBD-related complications, hospitalizations, sepsis, mortality. Quality of life and costs were assessed. Results: Five studies with 71,216 patients (49.1% with DM) were included. Risk for IBD-related complications (OR=1.12, I2 98% p = 0.77), mortality (OR=1.52, I2 98% p = 0.37) and IBD-related surgery (OR=1.20, I2 81% p = 0.26) did not differ. Risk of IBD-related hospitalizations (OR=2.52, I2 0% p < 0.00001) and sepsis (OR=1.56, I2 88% p = 0.0003) was higher in the IBD+DM group. Risk of pneumonia and urinary tract infections was higher in the IBD+DM group (OR=1.72 and OR=1.93), while risk of C. Difficile infection did not differ (OR=1.22 I2 88% p = 0.37). Mean Short Inflammatory Bowel Disease Questionnaire score was lower in the IBD+DM group (38.9 vs. 47, p = 0.03). Mean health care costs per year were $10,598.2 vs $3747.3 (p < 0.001). Conclusion: DM might negatively affect the course of IBD by increasing the risk of hospitalization and infections, but not IBD-related complications and mortality.
AB - Background: Diabetes Mellitus (DM) may occur in IBD and influence the disease progression. Aim: To compare disease course and treatment outcomes in IBD patients with and without DM. Methods: This is a systematic review with meta-analysis comparing patients with IBD plus DM with patients with IBD only. Primary endpoints: need for surgery, IBD-related complications, hospitalizations, sepsis, mortality. Quality of life and costs were assessed. Results: Five studies with 71,216 patients (49.1% with DM) were included. Risk for IBD-related complications (OR=1.12, I2 98% p = 0.77), mortality (OR=1.52, I2 98% p = 0.37) and IBD-related surgery (OR=1.20, I2 81% p = 0.26) did not differ. Risk of IBD-related hospitalizations (OR=2.52, I2 0% p < 0.00001) and sepsis (OR=1.56, I2 88% p = 0.0003) was higher in the IBD+DM group. Risk of pneumonia and urinary tract infections was higher in the IBD+DM group (OR=1.72 and OR=1.93), while risk of C. Difficile infection did not differ (OR=1.22 I2 88% p = 0.37). Mean Short Inflammatory Bowel Disease Questionnaire score was lower in the IBD+DM group (38.9 vs. 47, p = 0.03). Mean health care costs per year were $10,598.2 vs $3747.3 (p < 0.001). Conclusion: DM might negatively affect the course of IBD by increasing the risk of hospitalization and infections, but not IBD-related complications and mortality.
KW - Crohn's disease
KW - Diabetes mellitus
KW - Inflammatory bowel disease
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85138519031&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2022.08.017
DO - 10.1016/j.dld.2022.08.017
M3 - Review article
C2 - 36058820
AN - SCOPUS:85138519031
SN - 1590-8658
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
ER -
